ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $2.93 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Morgan Stanley: 'We still think it is very unlikely Coinbase voluntarily steps away from the Circle partnership'
• Citi Upgrades Page Industries Ltd. (PAG:IN) to Buy, Opens Positive 90-Day Catalyst Watch